Welcome!

News Feed Item

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Fatty Liver Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Fatty Liver Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Fatty Liver Disease Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Fatty Liver Disease 33
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 33
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck & Co., Inc. 35
Clinical Trial Overview of Merck & Co., Inc. 35
Galmed International Ltd. 36
Clinical Trial Overview of Galmed International Ltd. 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
PharmaKing Co., Ltd. 38
Clinical Trial Overview of PharmaKing Co., Ltd. 38
Abbott Laboratories 39
Clinical Trial Overview of Abbott Laboratories 39
TCM Biotech International Corp 40
Clinical Trial Overview of TCM Biotech International Corp 40
Sanofi 41
Clinical Trial Overview of Sanofi 41
Phenex Pharmaceuticals AG 42
Clinical Trial Overview of Phenex Pharmaceuticals AG 42
GW Pharmaceuticals plc 43
Clinical Trial Overview of GW Pharmaceuticals plc 43
Genextra S.p.a. 44
Clinical Trial Overview of Genextra S.p.a. 44
Clinical Trial Overview of Top Institutes / Government 45
The National Institute of Diabetes and Digestive and Kidney Diseases 45
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 45
Tabriz University of Medical Sciences 46
Clinical Trial Overview of Tabriz University of Medical Sciences 46
Third Military Medical University 47
Clinical Trial Overview of Third Military Medical University 47
University of Michigan 48
Clinical Trial Overview of University of Michigan 48
Tehran University of Medical Sciences 49
Clinical Trial Overview of Tehran University of Medical Sciences 49
Washington University School of Medicine 50
Clinical Trial Overview of Washington University School of Medicine 50
University of California, San Diego 51
Clinical Trial Overview of University of California, San Diego 51
FUDAN University 52
Clinical Trial Overview of FUDAN University 52
Ahvaz Jundishapur University of Medical Sciences 53
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences 53
Bambino Gesu Hospital and Research Institute 54
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 54
Five Key Clinical Profiles 55
Appendix 82
Abbreviations 82
Definitions 82
Research Methodology 83
Secondary Research 84
About GlobalData 84
Contact Us 84
Disclaimer 84
Source 85

List of Tables
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Fatty Liver Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 35
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2014* 36
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by PharmaKing Co., Ltd., 2014* 38
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 39
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by TCM Biotech International Corp, 2014* 40
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 41
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Phenex Pharmaceuticals AG, 2014* 42
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 43
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2014* 44
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014* 45
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tabriz University of Medical Sciences, 2014* 46
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Military Medical University, 2014* 47
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 48
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 49
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 50
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 51
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 52
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ahvaz Jundishapur University of Medical Sciences, 2014* 53
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2014* 54

List of Figures
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 83

Read the full report:
Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We view the cloud not really as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to imp...
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.